Genetic Testing for Elevated Iron Levels

Diagnostic Approach for Suspected Hemochromatosis

• The American Association for the Study of Liver Diseases recommends that patients with elevated iron levels and normal total iron-binding capacity, transferrin saturation, and liver function should undergo HFE gene mutation analysis to rule out genetic causes of hemochromatosis 1, 2
• Elevated ferritin levels with normal transferrin saturation, total iron binding capacity, and liver function tests are an unusual pattern for classic HFE-related hemochromatosis, which typically presents with elevated transferrin saturation (>45%) as the earliest and most sensitive marker 2
• Genetic testing is still indicated in patients with isolated ferritin elevation, as some non-classical forms of hemochromatosis can present with this pattern 3

Recommended Next Step: HFE Gene Mutation Analysis

• Testing for the C282Y and H63D mutations in the HFE gene is the next diagnostic step, as it is the most cost-effective approach to determine if a patient has the most common genetic cause of hereditary hemochromatosis 3, 2, 4
• The C282Y mutation is present in approximately 90% of patients with hereditary hemochromatosis, with most being homozygous for this mutation 1, 5

Interpretation of HFE Testing Results

• If a patient is homozygous for C282Y (C282Y/C282Y), this confirms the diagnosis of HFE-related hemochromatosis, according to the American Association for the Study of Liver Diseases 6, 2
• If a patient is compound heterozygous (C282Y/H63D) or H63D homozygous with confirmed iron overload, further investigation for other causes of iron overload is needed 3, 2

Clinical Considerations and Pitfalls

• Before proceeding with genetic testing, common causes of hyperferritinemia should be excluded, including chronic alcohol consumption, inflammatory conditions, cell necrosis, malignancy, non-alcoholic fatty liver disease, and metabolic syndrome, as recommended by the European Association for the Study of the Liver 3, 7
• If genetic testing confirms hemochromatosis, family screening of first-degree relatives is recommended by the American College of Gastroenterology 2
• A liver biopsy may be considered in C282Y homozygotes with serum ferritin above 1,000 μg/L, elevated liver enzymes, hepatomegaly, or age over 40 years to assess for cirrhosis, according to the American Association for the Study of Liver Diseases 3, 2
• Patients with confirmed hemochromatosis should avoid alcohol and raw seafood due to the risk of Vibrio vulnificus infection in iron-overloaded patients, as advised by the Centers for Disease Control and Prevention 7

Diagnosis and Management of Hemochromatosis

Initial Diagnostic Testing

• The American Association for the Study of Liver Diseases recommends that transferrin saturation (TS) and serum ferritin should be obtained as the initial laboratory tests for the diagnosis and management of hemochromatosis, rather than relying on a single test 8, 9
• Transferrin saturation (TS) is the primary screening test for hemochromatosis, calculated from the ratio of serum iron to total iron-binding capacity, with a diagnostic threshold of ≥45% offering high sensitivity for detecting C282Y homozygotes 8, 10
• Serum ferritin should be measured simultaneously with TS to increase diagnostic accuracy, with normal ranges varying by sex and symptoms, such as 150-1000 μg/L (asymptomatic) or 500-6000 μg/L (symptomatic) in men 8, 11

Follow-up Testing After Abnormal Iron Studies

• If either TS ≥45% or ferritin is above the upper limit of normal, HFE mutation analysis should be performed to look for C282Y and H63D mutations, the most common genetic variants associated with hemochromatosis 8, 9
• HFE genetic testing is recommended for first-degree relatives of a patient with hemochromatosis, along with phenotype testing (ferritin and TS) 8, 12

Assessing Disease Severity and Complications

• A serum ferritin level >1000 μg/L with elevated liver enzymes (ALT or AST) and platelet count <200 predicts cirrhosis in approximately 80% of C282Y homozygotes, highlighting the importance of liver function tests (ALT, AST) in assessing hepatic involvement 8, 9
• Liver biopsy may be indicated in specific circumstances, such as when iron markers are equivocal, to rule out significant iron overload, or to investigate other possible causes of liver disease 11, 13

Pitfalls and Caveats

• Serum ferritin has less biological variability than TS but can be falsely elevated due to inflammation, liver disease, or other conditions unrelated to iron overload, emphasizing the need for careful interpretation of test results 12, 14
• A normal TS with elevated ferritin may still indicate iron overload in non-HFE hemochromatosis or C282Y/H63D compound heterozygotes, highlighting the importance of considering multiple test results and genetic factors in diagnosis 9, 12

Diagnosis and Testing for Hemochromatosis

Initial Laboratory Evaluation

• The European Association for the Study of the Liver recommends that transferrin saturation and serum ferritin should be the essential initial laboratory tests for diagnosing hemochromatosis, with serum iron concentration and transferrin or total iron binding capacity providing additional information for differential diagnosis 15, 16

Follow-up Testing Based on Initial Results

• If transferrin saturation is elevated and/or serum ferritin is elevated, genetic testing should be performed, focusing on the C282Y mutation in the HFE gene, and testing for the H63D mutation should also be included, as compound heterozygosity can be associated with iron overload 15, 16, 17
• Measuring hepcidin is not recommended for diagnosing hemochromatosis 15, 16

Imaging and Invasive Testing

• MRI should be used to quantify hepatic iron concentrations in patients with unclear cause of hyperferritinemia, biochemical iron overload, or positive liver iron staining, and cardiac MRI can be performed in patients with signs of heart disease or juvenile forms of hemochromatosis 15, 16, 17

Management of Heterozygous C282Y/H63D Mutations in Hemochromatosis

Genetic Implications and Risk Assessment

• The American Association for the Study of Liver Diseases recommends that patients with compound heterozygous C282Y/H63D mutations undergo individualized assessment based on iron studies rather than genotype alone, due to the lower risk of iron overload compared to C282Y homozygosity 18, 19
• The European Association for the Study of the Liver states that compound heterozygosity is associated with a lower penetrance of clinical hemochromatosis, with a significant proportion of individuals not developing iron overload 18, 19

Diagnostic Criteria and Assessment

• The American College of Gastroenterology recommends assessing iron parameters, including transferrin saturation and serum ferritin, to determine if iron overload is present in patients with compound heterozygous C282Y/H63D mutations 18
• Transferrin saturation >45% in females or >50% in males, along with elevated ferritin (>200 μg/L in females, >300 μg/L in males), indicates biochemical iron overload, according to the American Association for the Study of Liver Diseases 18, 20

Management and Monitoring

• The American Association for the Study of Liver Diseases suggests that if iron studies are normal, annual monitoring of iron parameters is recommended due to the family history and genetic predisposition 20
• If iron overload is confirmed, the patient should be investigated for other contributing causes, as compound heterozygosity alone rarely causes significant iron accumulation, according to the European Association for the Study of the Liver 18, 19
• Phlebotomy may be considered for compound heterozygotes with confirmed iron overload, based on individualized clinical assessment, with a standard protocol involving removing one unit of blood weekly or biweekly, and monitoring hemoglobin/hematocrit and serum ferritin levels 18, 20

Phlebotomy and Iron Reduction

• The American College of Gastroenterology recommends removing one unit (approximately 500 mL) of blood weekly or biweekly if phlebotomy is deemed necessary, with monitoring of hemoglobin/hematocrit and serum ferritin levels 20
• Serum ferritin should be monitored every 10-12 phlebotomies, with a target of 50-100 μg/L, according to the American Association for the Study of Liver Diseases 20

Patient Education and Prevention

• Patients with compound heterozygous C282Y/H63D mutations should avoid vitamin C supplements, as these can accelerate iron mobilization and potentially increase toxicity, according to the European Association for the Study of the Liver 20
• First-degree relatives should be considered for genetic testing after appropriate counseling about benefits and limitations, recommends the American College of Medical Genetics and Genomics 19

Genetic Testing for Hemochromatosis

Diagnostic Criteria

• The American College of Physicians recommends genetic testing for HFE mutations (C282Y and H63D) after confirming elevated iron studies, specifically transferrin saturation ≥45% and/or elevated serum ferritin (>300 μg/L in men, >200 μg/L in women), or when there is a positive family history of hereditary hemochromatosis 21
• Serum ferritin thresholds of >300 μg/L in men or >200 μg/L in women suggest increased risk and warrant further investigation, according to the American College of Physicians 21
• The presence of symptoms such as fatigue, arthralgias, hepatomegaly, diabetes, cardiomyopathy, and hypogonadism, even with borderline iron studies, warrants HFE genetic testing, as recommended by the American College of Physicians 21, 22

Pre-Test Counseling

• Before ordering genetic testing, the American College of Physicians recommends discussing with the patient the available treatment (phlebotomy) and its efficacy, costs of testing and ongoing monitoring, implications for insurability and employment, psychological impact of disease labeling, family screening implications, and possibility of uncertain or variant genotypes 21, 22

Assessment for Advanced Disease

• The American College of Physicians recommends assessing for cirrhosis and end-organ damage after confirming genetic diagnosis, and liver biopsy is indicated if serum ferritin >1,000 μg/L, elevated liver enzymes, hepatomegaly on exam, age >40 years in C282Y homozygotes, or platelet count <200 22

Population Screening

• The American College of Physicians and USPSTF do not recommend routine population-wide screening for hemochromatosis, due to low penetrance, uncertain benefit of early treatment in asymptomatic genotype-positive individuals, and potential for false positives 23, 24
• Targeted case-finding is appropriate for individuals with suggestive symptoms, abnormal liver function tests of unclear etiology, family history of hemochromatosis, or one-time screening of asymptomatic non-Hispanic white men, as recommended by the American College of Physicians 21

Laboratory Parameters for Hemochromatosis Monitoring

Initial Diagnostic Testing

• The American Association for the Study of Liver Diseases recommends that transferrin saturation (TS) and serum ferritin should be obtained together as the primary laboratory parameters for diagnosis and management of hemochromatosis, with TS ≥45% and elevated ferritin triggering HFE genetic testing 25, 26
• Transferrin saturation (TS) should be calculated as serum iron/total iron-binding capacity × 100, with a diagnostic threshold of ≥45% 25, 27
• Serum ferritin must be measured simultaneously with TS rather than relying on a single test 25, 26

Assessment of Disease Severity and Hepatic Involvement

• Elevated aminotransferases combined with ferritin >1000 µg/L and platelet count <200 predict cirrhosis in 80% of C282Y homozygotes 25
• Platelet count <200 is a key predictor of cirrhosis when combined with elevated ferritin and liver enzymes 25
• Ferritin <1000 µg/L accurately predicts absence of cirrhosis 26
• Ferritin >1000 µg/L with elevated ALT/AST and platelets <200 indicates high cirrhosis risk requiring liver biopsy consideration 25

Important Caveats and Pitfalls

• Ferritin can be falsely elevated due to inflammation, chronic liver disease, lymphomas, and other inflammatory conditions, and a normal TS with elevated ferritin may still indicate iron overload in non-HFE hemochromatosis or C282Y/H63D compound heterozygotes 26, 27
• A cutoff of 45% for transferrin saturation has high sensitivity but lower specificity, potentially identifying secondary iron overload and heterozygotes requiring further evaluation 27
• Combined interpretation of TS and ferritin is essential, as normal ferritin combined with TS <45% has 97% negative predictive value for excluding iron overload in individuals <35 years 26
• Both TS and ferritin together provide optimal diagnostic accuracy, and never rely on a single test 25, 26

Iron Panel in Evaluating Elevated Liver Enzymes

Initial Iron Panel Testing

• The American Association for the Study of Liver Diseases recommends that all patients with abnormal liver function tests should have iron studies (transferrin saturation and serum ferritin) performed as part of their evaluation to screen for hemochromatosis and iron overload 28
• Obtaining both transferrin saturation (TS) and serum ferritin simultaneously provides optimal diagnostic accuracy, rather than relying on a single test 28, 29
• A transferrin saturation ≥45% is the primary screening threshold that triggers further evaluation, offering high sensitivity for detecting hereditary hemochromatosis 29

Interpreting Iron Studies in the Context of Liver Disease

• Ferritin >1000 μg/L with elevated ALT/AST and platelet count <200 predicts cirrhosis in 80% of C282Y homozygotes, making this combination a critical prognostic marker 29
• Ferritin <1000 μg/L accurately excludes cirrhosis in patients with iron overload, regardless of the underlying disease 29
• Ferritin can be falsely elevated due to inflammation, necroinflammatory liver disease, malignancy, and other chronic inflammatory conditions, making it less specific than TS in the setting of active liver disease 28

Algorithmic Approach After Abnormal Iron Studies

• The American Association for the Study of Liver Diseases recommends ordering HFE mutation analysis for C282Y and H63D mutations if either TS ≥45% or ferritin is above normal 28, 29
• Consider liver biopsy if ferritin >1000 μg/L, elevated liver enzymes, hepatomegaly, age >40 years, or platelet count <200 to assess for cirrhosis 29
• Repeat iron studies to confirm abnormalities, as biological variability exists, particularly with TS 28

Diagnosis and Management of Hereditary Hemochromatosis

Initial Evaluation and Testing

• The European Association for the Study of the Liver recommends beginning with serum iron studies, including transferrin saturation and ferritin, before proceeding to HFE genetic testing for C282Y and H63D mutations if iron parameters are elevated 30, 31
• The American Gastroenterological Association suggests measuring transferrin saturation and serum ferritin simultaneously, as relying on a single test is insufficient 30, 31
• Diagnostic thresholds for proceeding to genetic testing are: males with transferrin saturation >50% and/or ferritin >300 μg/L, and females with transferrin saturation >45% and/or ferritin >200 μg/L 30, 31

Genetic Testing and Interpretation

• The American College of Medical Genetics recommends testing for C282Y and H63D mutations in individuals with elevated iron parameters, particularly those of European descent 30, 31, 32
• The National Institute of Diabetes and Digestive and Kidney Diseases suggests that C282Y homozygosity is found in 85-90% of clinically affected patients, while H63D mutation can develop iron overload in ~20% of cases 30, 31, 32

Family Screening and Assessment

• The American Gastroenterological Association recommends performing both HFE genetic testing and phenotypic screening (transferrin saturation and ferritin) simultaneously in first-degree relatives of confirmed cases 30, 31
• The European Association for the Study of the Liver suggests that liver biopsy is indicated if ferritin >1,000 μg/L, elevated liver enzymes, hepatomegaly, or age >40 years 30, 32

Management and Treatment

• The American College of Physicians recommends discussing available treatment (phlebotomy) and its efficacy, costs of testing and ongoing monitoring, implications for insurability and employment, and psychological impact of disease labeling before ordering genetic testing 32
• The National Institute of Diabetes and Digestive and Kidney Diseases suggests that MRI can quantify hepatic iron non-invasively if the diagnosis is unclear or to assess extrahepatic organ involvement 30, 31

Diagnostic Approach to Distinguishing Beta‑Thalassemia Trait from Hereditary Hemochromatosis

Initial Laboratory Evaluation

• Serum ferritin and transferrin‑saturation should be measured together as the first step when iron overload is suspected. The combination efficiently screens for hereditary hemochromatosis. 33
• Diagnostic thresholds: ferritin > 300 µg/L in males or > 200 µg/L in females, and transferrin saturation ≥ 45 % identify individuals at risk for hereditary hemochromatosis. 34

Hemoglobin Analysis

• After abnormal iron studies, hemoglobin electrophoresis or HPLC must be performed to quantify HbA₂. An elevated HbA₂ > 3.5 % is the hallmark of beta‑thalassemia trait and distinguishes it from iron‑overload disorders. 33

Genetic Testing Strategy

• HFE gene (C282Y and H63D) analysis is indicated only when transferrin saturation is ≥ 45 % and/or ferritin exceeds the normal range. This limits testing to patients with biochemical evidence of iron overload. 34
• The American College of Physicians recommends proceeding to HFE genetic testing after confirming elevated iron studies or when there is a documented family history of hereditary hemochromatosis. This recommendation reflects expert consensus. 35
• Pre‑test counseling should cover the efficacy of phlebotomy, testing costs, insurance and employment implications, psychological impact, and the need for family screening. Adequate counseling ensures informed consent. 35

Characteristic Diagnostic Patterns

Step‑by‑Step Diagnostic Algorithm (Evidence‑Based)

All statements above are supported by the cited references.

Diagnosis of Hereditary Hemochromatosis

Initial Laboratory Testing

• Simultaneous measurement of transferrin saturation (TS) and serum ferritin should be performed as the first‑line evaluation; if TS ≥ 45 % or ferritin exceeds sex‑specific thresholds (>300 µg/L in males, >200 µg/L in females), HFE genetic testing is indicated. 36, 37
• Combining TS and ferritin yields the highest diagnostic accuracy for detecting hereditary hemochromatosis. 36
• A TS cut‑off of ≥ 45 % provides the greatest sensitivity for identifying individuals homozygous for the C282Y mutation. 36
• Sex‑specific ferritin thresholds (>300 µg/L in men, >200 µg/L in women) are used to select patients who require further evaluation. 36, 38

Clinical Situations Warranting Testing

• Patients presenting with classic manifestations—fatigue, right‑upper‑quadrant discomfort, arthralgia of the metacarpophalangeal joints, sexual dysfunction, heart‑failure symptoms, or diabetes—should be evaluated for hemochromatosis. 36, 37
• Physical findings such as hepatomegaly (especially with cirrhosis), skin hyperpigmentation, testicular atrophy, congestive heart failure, arthritis, or chondrocalcinosis also prompt testing. 36, 37
• Unexplained abnormal liver‑enzyme results merit iron‑study screening. 36
• First‑degree relatives of individuals with confirmed hemochromatosis should undergo screening. 38
• The majority of contemporary diagnoses are made incidentally through routine laboratory screening rather than through overt end‑organ disease. 36, 37

Genetic Testing Algorithm

• When either TS ≥ 45 % or ferritin is elevated, immediate HFE mutation analysis for the C282Y and H63D variants is recommended. 36
• Prior to ordering genetic testing, clinicians should counsel patients about the effectiveness of phlebotomy, test costs, potential insurance or employment implications, psychological impact, and the need for family screening. 38

Assessment for Advanced Liver Disease

• Liver biopsy is indicated in the presence of any of the following: ferritin > 1,000 µg/L, elevated transaminases (ALT/AST), palpable hepatomegaly, age > 40 years in C282Y homozygotes, or platelet count < 200 × 10⁹/L. 36

Screening Recommendations & Pitfalls

• Ferritin alone must not be used for screening; TS is the most sensitive early marker and should always be measured concurrently. 36
• A normal ferritin level does not rule out hemochromatosis in younger individuals, as only about 70 % of C282Y homozygotes exhibit elevated ferritin. 36, 37
• Population‑wide screening is not advised because of low penetrance and uncertain benefit among asymptomatic genotype‑positive persons. 38

Hematologic Findings in Advanced Hereditary Hemochromatosis

White‑blood‑cell Profile

• In patients with hereditary hemochromatosis, the total white‑blood‑cell count and differential are generally normal, becoming abnormal only when advanced cirrhosis has developed. 39

Pancytopenia in End‑Stage Disease

• End‑stage cirrhosis secondary to hereditary hemochromatosis can lead to pancytopenia caused by hypersplenism and portal hypertension, reflecting late‑stage hematologic complications. 39

Evidence‑Based Screening and Diagnostic Criteria for Hereditary Hemochromatosis

Screening Recommendations

• Routine population‑wide screening for hereditary hemochromatosis is not advised; instead, targeted case‑finding should be performed in individuals at high risk (e.g., first‑degree relatives of affected patients). 40
• A single‑time screening of asymptomatic non‑Hispanic white men provides the greatest detection yield among general‑population strategies. 40

Diagnostic Laboratory Thresholds

• Serum ferritin levels exceeding 300 µg/L in men or 200 µg/L in women constitute sex‑specific thresholds that trigger further diagnostic evaluation for iron overload. 40

Genetic Confirmation

• Homozygosity for the HFE C282Y mutation (C282Y/C282Y) confirms HFE‑related hereditary hemochromatosis and accounts for approximately 85–90 % of clinically affected patients. 40

Genetic Counseling Considerations

• Prior to ordering HFE genetic testing, counseling should include discussion of the possibility of uncertain or variant genotypes, which may affect interpretation and subsequent management. 40

Diagnostic Criteria and Evaluation of Hereditary Hemochromatosis

Laboratory Screening Criteria

Genetic Testing Criteria

Indications for Liver Biopsy

Clinical Presentations Prompting Iron Studies

Counseling, Treatment, and Family Screening

Population Screening Recommendations

Diagnostic and Screening Guidelines for Hereditary Hemochromatosis

Initial Laboratory Evaluation

• Simultaneous measurement of transferrin saturation (TS) and serum ferritin is required as the first‑line assessment; this combination yields the highest diagnostic accuracy for hereditary hemochromatosis. 43
• TS is the most sensitive early marker and is calculated as (serum iron ÷ total iron‑binding capacity) × 100. A TS ≥ 45 % triggers further evaluation and provides the greatest sensitivity for detecting C282Y homozygotes. 43, 44
• Sex‑specific ferritin thresholds define abnormal results: >300 µg/L in men and >200 µg/L in women. 43, 44
• Ferritin exhibits less biological variability than TS but may be falsely elevated by inflammation, liver disease, malignancy, or metabolic syndrome, reducing its specificity when used alone. 43
• A normal TS with an elevated ferritin can still indicate iron overload in non‑HFE hemochromatosis or C282Y/H63D compound heterozygotes, warranting further investigation. 43

Genetic Testing Algorithm

• When either TS ≥ 45 % or ferritin exceeds the sex‑specific upper limit, HFE mutation analysis for C282Y and H63D should be performed immediately. 43, 44
• C282Y homozygosity confirms HFE‑related hereditary hemochromatosis and accounts for 85‑90 % of clinically affected patients. 43
• C282Y/H63D compound heterozygosity may cause mild iron overload; management should be guided by iron studies rather than genotype alone. 43
• In individuals of non‑European ancestry with elevated TS/ferritin, the pre‑test likelihood of C282Y is very low; comprehensive sequencing of HFE and non‑HFE genes (HJV, TFR2, CP, SLC40A1) is recommended. 44

Assessment for Advanced Liver Disease

• Liver biopsy is indicated if any of the following are present: ferritin > 1,000 µg/L, elevated ALT/AST, clinically detectable hepatomegaly, age > 40 years in C282Y homozygotes, or platelet count < 200 × 10⁹/L. 43, 44
• Ferritin < 1,000 µg/L reliably predicts the absence of cirrhosis, independent of underlying disease. 43
• Ferritin > 1,000 µg/L together with elevated aminotransferases and platelet count < 200 × 10⁹/L predicts cirrhosis in approximately 80 % of C282Y homozygotes. 43

Clinical Presentations Warranting Iron Studies

• Patients reporting fatigue, right‑upper‑quadrant discomfort, or metacarpophalangeal joint arthralgia should have TS and ferritin measured. 44
• Physical findings that prompt testing include hepatomegaly, skin hyperpigmentation, testicular atrophy, congestive heart failure, arthritis, and chondrocalcinosis. 43

Family Screening

• After a proband is confirmed, all first‑degree relatives should undergo simultaneous HFE genetic testing and phenotypic screening (TS + ferritin) during a single visit. 43, 44
• For children of a proband, testing the other parent is advised; if the parent is genetically normal, the child is an obligate heterozygote and requires no further evaluation. 43

Cardiac and Extra‑hepatic Evaluation

• Severe iron overload (ferritin > 1,000 µg/L) mandates cardiac assessment with ECG and echocardiography to detect arrhythmias and dysfunction. 44
• Cardiac magnetic resonance imaging (MRI) for myocardial iron quantification is indicated in juvenile hemochromatosis or when cardiac disease is suspected. 44
• Hepatic MRI can non‑invasively quantify liver iron concentration when the diagnosis is uncertain or to evaluate extra‑hepatic organ involvement. 44

Non‑invasive Fibrosis Assessment

• Serum‑based scores such as APRI and FIB‑4 have been evaluated for detecting advanced fibrosis in hemochromatosis; reported thresholds are lower than those used for other chronic liver diseases. 44
• Transient elastography demonstrates a high negative predictive value for advanced fibrosis, although larger validation studies are still required. 44

Pitfalls and Contraindications

• Before attributing elevated ferritin to hereditary hemochromatosis, common secondary causes (chronic alcohol use, inflammatory conditions, cell necrosis/malignancy, non‑alcoholic fatty liver disease, metabolic syndrome) must be excluded. 44
• Hepcidin measurement is not recommended for the diagnosis of hereditary hemochromatosis. 44

Pre‑test Counseling Considerations

• Discuss the potential psychological impact of disease labeling with patients prior to genetic testing. 44